Will Kane brings over 30 years of experience in strategy development, operations, and new product planning to Anthos. He has led businesses across a broad range of therapeutic areas, including the cardiometabolic space. Mr. Kane most recently served as Chief Commercial Officer at Karuna Therapeutics and has held senior level commercial positions at BioXcel Therapeutics, Allergan, and Pfizer; he was an integral part of launching several successful brands, including CELEBREX® for the treatment of arthritis, NAMZARIC® for Alzheimer’s disease, VRAYLAR® for the treatment of schizophrenia and bipolar disorder, and UBRELVY™, the first oral calcitonin gene-related peptide (CGRP) for the acute treatment of migraine.
Will Kane received his MBA from The Wharton School at the University of Pennsylvania and a B.A. in Government from Connecticut College.